XML 59 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Balance Sheets (USD $)
Jun. 30, 2013
Dec. 31, 2012
Current assets:    
Cash and cash equivalents $ 10,352,170 $ 5,646,021
Short-term investments 13,107,779 8,034,001
Accounts receivable 540,345 830,433
Accounts receivable from affiliated entity 0 36,234
Prepaid expenses and other current assets 710,289 471,328
Prepaid expenses and other current assets from affiliated entity 763,357 887,167
Deferred tax asset 62,728 62,728
Total current assets 25,536,668 15,967,912
Restricted cash 100,586 100,410
Fixed assets, net 348,119 363,021
Investment in affiliated entity 7,835,197 10,703,332
Intangible assets, net 6,596,287 7,489,315
Goodwill 10,113,371 [1] 10,113,371 [1]
Common stock warrants 265,500 267,200
Other assets 197,143 134,193
Total assets 50,992,871 45,138,754
Current liabilities:    
Accounts payable and accrued expenses 3,336,480 3,181,574
Accounts payable and accrued expenses due to affiliated entity 45,287 187,275
Accrued clinical trial expenses 1,732,247 1,405,896
Common stock warrants 13,453,937 2,859,899
Deferred revenue 89,828 353,391
Deferred revenue from affiliated entity 413,541 388,542
Total current liabilities 19,071,320 8,376,577
Deferred revenue, net of current portion 85,286 88,609
Deferred revenue from affiliated entity, net of current portion 1,399,194 1,586,694
Deferred rent 601,077 65,076
Deferred tax liabilities 164,393 164,393
Total liabilities 21,321,270 10,281,349
Inovio Pharmaceuticals, Inc. stockholders’ equity:    
Common stock 180,059 144,313
Additional paid-in capital 278,570,240 263,897,116
Accumulated deficit (249,456,837) (229,760,129)
Accumulated other comprehensive (loss) income (96,436) 73,362
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 29,197,026 34,354,662
Non-controlling interest 474,575 502,743
Total stockholders' equity 29,671,601 34,857,405
Total liabilities and stockholders’ equity $ 50,992,871 $ 45,138,754
[1] Goodwill was recorded from the Inovio AS acquisition in January 2005 and from the acquisition of VGX in June 2009 for $3.9 million and $6.2 million, respectively.